$22.04
-0.24 (-1.08%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where STRO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 11 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, +6 more) · FINRA short interest 6.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | Dec 2027 | ≤ 499 d | 2026-08-06 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1NCT05870748Progression Free Survival (PFS)Randomized · Open-label · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta | Drug: Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer | 600 | 2025-08-26actual | — | 2025-09-23 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerNCT05200364Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapyOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Terminated Early | Drug: STRO-002, Bevacizumab | Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 58 | 2025-06-01actual | — | 2025-09-22 |
| Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLNCT06679582Evaluate efficacy of luveltamab tazevibulin monotherapyRandomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Terminated Early | Drug: Luveltamab tazevibulin | Acute Myeloid Leukemia (AML) | 24 | 2025-06-01actual | — | 2025-08-24 |
| Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung CancerNCT06555263Objective Response Rate (ORR)Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Terminated Early | Drug: Luveltamab tazevibulin | Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell | 0 | 2025-05-01actual | — | 2025-08-22 |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersNCT03748186Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)Open-label · Treatment | Phase 1 | Completed | Drug: STRO-002 | Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 136 | 2024-06-04actual | — | 2025-08-20 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesNCT03424603Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001)Open-label · Treatment | Phase 1 | Completed | Drug: STRO-001 | B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors | 70 | 2024-02-15actual | — | 2024-06-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19